A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort
在种族多元化的人群中,每周低剂量地西他滨和维奈托克方案疗效显著且骨髓毒性较低。
期刊:Blood
影响因子:23.1
doi:10.1182/blood.2024025834
Goldfinger, Mendel; Mantzaris, Ioannis; Shastri, Aditi; Saunthararajah, Yogen; Gritsman, Kira; Sica, R Alejandro; Kornblum, Noah; Shah, Nishi; Levitz, David; Rockwell, Bradley; Shapiro, Lauren C; Gupta, Ridhi; Pradhan, Kith; Xue, Xiaonan; Munoz, Anne; Dhawan, Aradhika; Fehn, Karen; Comas, Monica; Verceles, Jhannine Alyssa; Jonas, Brian A; Kambhampati, Suman; Shi, Yang; Braunschweig, Ira; Cooper, Dennis L; Konopleva, Marina; Feldman, Eric J; Verma, Amit